Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool aims to cut risky drug combos in seniors, but trial stalls

NCT ID NCT04710615

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an artificial intelligence platform called Synapse to help doctors avoid dangerous drug interactions in older patients (65+). The goal was to see if the AI could reduce inappropriate prescriptions when patients left the hospital. However, the trial was terminated early, so we don't have enough data to know if it worked. The study involved 178 older adults in French hospitals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Synapse platform (AI virtual assistant for medication review)
What this could lead to
If successful, this could help doctors prescribe safer medications for older adults by catching harmful drug interactions.
What could go wrong
The trial was terminated early, so we don't have clear results. It's unclear if the AI platform actually improves prescribing in real-world hospital settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

178 people

The number who actually took part.

Started

Oct 2021

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion criteria: * Male or female age aged more than 65 years * Hospitalization in geriatric department at Bordeaux University Hospital or Libourne Hospital * Initial drug prescription with at least 2 active pharmaceutical ingredients * Affiliation to French social security * Written informed consent signed by participant and investigator * Exclusion criteria: * Adults protected by law * Subject included in a clinical trial with an experimental treatment * Subject during exclusion period relative to another trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-drug interactions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug-drug interactions Geriatric disease

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33000, France

  • CHU de Bordeaux, Hôpital Pellegrin

    Bordeaux, 33000, France

  • CHU de Bordeaux, Hôpital Xavier Arnozan

    Pessac, 33400, France

  • CHU de Bordeaux, Hôpital Xavier Arnozan

    Pessac, 33600, France

  • Centre Hospitalier de Libourne - Pôle Gériatrie

    Libourne, 33500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.